Seres Therapeutics (MCRB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jul, 2026Opening remarks and agenda
Meeting called to order with introductions of executive team, board members, auditor, and inspector of election.
Agenda and rules of conduct provided on the virtual meeting webpage.
Board and executive committee updates
Election of Stephen Berenson, Claire Fraser, and Richard Kender as Class II Directors for a term expiring at the 2029 Annual Meeting.
Shareholder proposals
Five proposals presented: director elections, auditor ratification, executive compensation advisory vote, amendment to the 2025 Incentive Award Plan, and potential adjournment to solicit proxies.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Seres Therapeutics
- SER-155 achieved 80% immunosuppressive-free response in irEC with strong safety and biomarker support.MCRB
Study result9 Jul 2026 - SER-155 delivers 77% risk reduction in bloodstream infections, driving pipeline momentum.MCRBCompany presentation8 Jul 2026
- AI-driven microbiome therapeutics pipeline advances toward key clinical and commercial milestones.MCRBH.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026
- Leadership changes and SER-155 data in Q2 2026, with cash runway through Q3 2026.MCRBStatus update11 May 2026
- Q1 2026 net loss of $19.9M, $29.8M cash, runway through Q3, and urgent need for new funding.MCRBQ1 20265 May 2026
- Virtual meeting to vote on directors, auditor, compensation, and incentive plan amendment.MCRBProxy filing27 Apr 2026
- Shareholders will vote on director elections, auditor ratification, executive pay, and an expanded equity plan.MCRBProxy filing27 Apr 2026
- Returned to profitability in 2025, focusing on SER-155 and SER-603, with cash runway into Q3 2026.MCRBQ4 202512 Mar 2026
- VOWST sale to Nestlé secures $155M upfront, funds pipeline, and extends cash runway into late 2025.MCRBInvestor Update2 Feb 2026